China could approve first fully AI-designed drug next year, Merck executive says

South China Morning PostCenter-RightEN 1 min read 100% complete by Julie ZhangJanuary 27, 2026 at 01:00 PM

AI Summary

short article 1 min

According to Merck China's president, Marc Horn, China could approve the first fully AI-designed drug as early as next year, potentially making it a global leader in this area. This prediction is based on China's advancements in AI, human genetics, and its growing biopharmaceutical sector, which has shifted from generics to innovative drug development. China's drug makers saw a record US$135.7 billion in out-licensing deals last year. Horn noted that approximately 30% of new drug pipelines originate from China, supported by large patient data sets and the government's "AI Plus" program, a national initiative designed to promote AI development across various sectors. The "AI Plus" program aims to propel China into a new era of "intelligent civilization."

Key Entities & Roles

Key Player Opposition Context

Hong Kong 40% Asian Financial Forum 40% AI Plus ×260% Merck 70% Marc Horn ×270% China ×690%

Keywords

ai-designed drug 100% artificial intelligence 90% drug development 80% china 70% biopharmaceutical sector 60% ai plus 50% drug pipelines 50% merck 40% out-licensing deals 40%